Protagonist Therapeutics, Inc. (PTGX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
7707 Gateway Boulevard
Newark, CA 94560-1160
United States of America (the)
Phone
510 474 0170
Sector
Healthcare
Industry
Biotechnology
Employees
124
First IPO Date
August 11, 2016
| Name | Title | Pay | Year Born |
| Dinesh V. Patel | Chief Executive Officer, President, Secretary & Director | 1.41M | 1957 |
| Asif Ali | Executive Vice President & Chief Financial Officer | 826,242 | 1974 |
| Arturo Molina FACP | Chief Medical Officer | 949,992 | 1959 |
| Carena Spivey | Executive VP & Chief Human Resources Officer | 0 | N/A |
| Ashok Bhandari | EVP & Chief Discovery Officer | 0 | 1964 |
| Newman Yeilding | Executive Vice President, Chief Scientific Officer | 0 | N/A |
| Samuel R. Saks | Clinical Development Advisor | 0 | 1955 |
| Carter J. King | Executive Vice President of Business Development | 0 | 1971 |
| Matthew Gosling | Executive Vice President and Chief Legal & Business Officer | 0 | 1971 |
| Venkat Thalladi | EVP & Chief Technical Officer | 0 | N/A |
| Abha Bommireddi | Executive Vice President & Chief of Staff | 0 | N/A |
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.